Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine dose-ranging with sufentanil for PCIA after laparoscopic colorectal cancer surgery
ChiCTR2600126992Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in colorectal cancer (CRC) (4 arms), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoints: NRS pain score at rest, NRS pain score on movement and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600126992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126992.